The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a gain of 50.73%.However, over the last six months, we can see a weaker performance of 107.00%. Over the last 30 days, the price of TRVI has leaped by -2.20%. And in the last five days, it has fallen by -4.46%.
Trevi Therapeutics Inc experienced a rather steady stock market performance. The highest value in the past year was recorded at $7.39 on 03/10/25 and the lowest value was $2.30 on 06/10/24.
52-week price history of TRVI Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Trevi Therapeutics Inc’s current trading price is -15.97% away from its 52-week high, while its distance from the 52-week low is 170.00%. The stock’s price range during this period has varied between$2.30 and $7.39. The Trevi Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 0.57 million for the day, a figure considerably lower than their average daily volume of 2.31 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Trevi Therapeutics Inc (TRVI) has experienced a quarterly rise of 44.08% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 631.83M and boasts a workforce of 26 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 5.32, with a change in price of +1.91. Similarly, Trevi Therapeutics Inc recorded 1,696,113 in trading volume during the last 100 days, posting a change of +44.73%.
TRVI’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for TRVI stands at 0.01. Similarly, the long-term debt-to-equity ratio is also 0.01.
TRVI Stock Stochastic Average
Trevi Therapeutics Inc’s raw stochastic average for the past 50 days is presently 55.65%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 22.06%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 11.02% and 18.83%, respectively.
